Genetic Abnormalities in Acute Myeloid Leukemia: Insights into Acute Myeloid Leukemia, Myelodysplasia-Related

Read full text Summarise with VIRAT
Authors: Seongjin Cho, Young Kyung Lee, Yonggeun Cho, Sangkeun Park, B. Han, Sejin Kim
Cited by: 0
References: 24

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the clonal proliferation of undifferentiated myeloid precursors.The advent of next-generation sequencing (NGS) has enabled the identification of diverse genetic alterations.We employed NGS to assess the genetic profiles of Korean patients with AML.Methods: We retrospectively analyzed 71 adult patients who were diagnosed with AML by bone marrow examination and underwent genetic studies, including NGS, at Hallym University Sacred Heart Hospital between February 2021 and March 2025.AML subtypes were classified based on the WHO Classification of Haematolymphoid Tumours (5th edition).Genetic abnormalities were compared across AML subtypes to assess distinctions between them.Results: Each patient harbored at least two genetic variants, with an average of 7.25 variants per patient.The most frequent variants were observed in DNMT3A (26.8%),FLT3 (26.8%), and NRAS (22.5%).Among the AML subtypes, AML, myelodysplasia-related (AML-MR) was the most common, accounting for 26 of 71 patients (36.6%).The average number of genetic variants per case was 7.92 in AML-MR and 6.89 in non-AML-MR, with no statistically significant difference (P =0.239).TP53 variants were significantly more frequent in AML-MR than in non-AML-MR (P

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Cancer Genomics and Diagnostics

Publication details

Journal / source
Laboratory Medicine Online
Volume
16
Issue
2
Pages
113–121
Publication date
27 March 2026
Language
EN